Review Course on Breast Cancer and Hematologic Issues: A Symposium to present highlights of the 2017 SABCS and the 2017 ASH Annual Meetings

This program happened in the past, and no dates are currently scheduled.

Select this button to navigate the sections of this page

Conference ID

J6217

Purpose

This program is designed to bring information learned at national meetings back to the central Pennsylvania area for physicians and other healthcare professionals to use in their daily clinical practices. The topics chosen represent material presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) and the 2017 American Society of Hematology (ASH) meetings.

This activity is not endorsed by or affiliated with SABCS or ASH.

Goals

  • Present the latest scientific information from the national meetings
  • Review treatment and research findings
  • Assess implications for clinical practice

Audience

Physicians and other health-care professionals

Credit

AMA

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Penn State College of Medicine designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses Using AMA Credit

Nurses will receive a certificate from Penn State College of Medicine verifying their participation in 5.5 hours of approved continuing medical education. Continuing education activities which are approved by accredited institutions of higher education and that are relevant to patient care or professional nursing meet the requirements of mandatory continuing education for registered nurses in Pennsylvania, as required by the Pennsylvania State Board of Nursing. The Board of Nursing recommends that nurses retain their certificates for a period of at least five years. Additional information is available through the State Board of Nursing.

Objectives

  • Increase knowledge regarding the treatment of patients with leukemia, through interactive case discussion
  • Distinguish good and poor molecular prognostic markers in acute myeloid leukemia (AML)
  • Identify patients who require ovarian suppression in the adjuvant setting
  • Review the current indications for axillary dissection in the management of primary breast cancer
  • Appreciate the current role of tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) management
  • Highlight the clinical trials leading to new approvals and evolving paradigm shifts in Hodgkin’s lymphoma
  • Discuss emerging treatment strategies, including immunotherapy, targeted agents, and chimeric antigen receptor (CAR) T-cell therapy
  • Emphasize the importance in improving long-term outcomes and minimizing treatment-related toxicities
  • Describe the clinical molecular markers of late relapse in estrogen receptor-positive (ER+) breast cancer
  • Review novel biomarkers of breast cancer therapy, and the potential of new inhibitors of related molecular pathways
  • Increase knowledge regarding the treatment of patients with breast cancer, through interactive case discussion
  • Become familiar with the management of thrombocytopenia in pregnancy
  • Explore options in the management of iron deficiency in pregnancy
  • Recognize and manage thromboembolic complications in pregnancy
  • Identify mechanisms of the interaction of cancer and thrombogenesis
  • Appropriately use new oral anticoagulants in cancer patients
  • Describe the potential of new inhibitors of actionable molecular pathways
  • Review mechanisms of poly (ADP-ribose) polymerase (PARP) inhibition
  • Assess activity of PARP inhibitors in BRCA-mutated breast cancer
  • Appreciate the role of combining immunotherapy with standard chemotherapy
  • Identify toxicities of palbociclib, ribociclib and abemociclib

Agenda

7:30 a.m. – 4 p.m.

  • 7:30 a.m. | Check-in / Continental Breakfast / Visit Exhibits
  • 8 a.m. | Welcome
    Harold A. Harvey, MD
  • 8:05 a.m. | Case Discussion: Leukemia
  • 8:30 a.m. | AML – Recent Advances
    David F. Claxton, MD
  • 9 a.m. | Advances in Hormonal Therapy, Ovarian Suppression and Therapy Duration
    Harold A. Harvey, MD
  • 9:20 a.m. | Axila in 2018: Is Axillary Dissection Necessary – Why or Why Not?
    Kristine L. Widders, MD
  • 9:40 a.m. | Break / Visit Exhibits
  • 10 a.m. | Stem Cell Biology – A Way to Understanding CML
    Witold Rybka, MD
  • 10:20 a.m. | Updates in Hodgkin’s Lymphoma
    Kevin Rakszawski, MD
  • 10:40 a.m. | Adjuvant Therapies – Can We Determine Duration?
    Harold A. Harvey, MD
  • 11 a.m. | Biomarkers and Molecular Pathways of Interest
    Kim Leitzel, MSc
  • 11:20 a.m. | Lunch / Visit Exhibits
  • 12:45 p.m. | Case Discussion: Breast Cancer
  • 1:30 p.m. | Common Hematologic Problems in Pregnancy
    Ricardo Carter, MD
  • 1:50 p.m. | Cancer-Related Thrombosis
    Matthew S. Evans, MD
  • 2:10 p.m. | Novel Concepts and Therapies
    Suhail Ali, MD
  • 2:30 p.m. | Break / Visit Exhibits
  • 2:55 p.m. | New PARP Inhibitor – EMBRACA Study Result
    Harold A. Harvey, MD
  • 3:15 p.m. | Novel Approaches in Management of Myelodysplastic Syndromes (MDS) Beyond Conventional Hypomethylating Agents
    Muhammad Hussain, MD
  • 3:35 p.m. | Pooled Analysis of Cyclin-Dependent Kinases 4/6 (CDK) Inhibitors in Older Women with Estrogen Receptor-Positive (ER+) Breast Cancer
    Cristina Truica, MD
  • 4 p.m. | Adjournment

Faculty

Suhail Ali, MD
Associate Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Chief of Oncology
Lebanon Veterans Administration Hospital

Ricardo Carter, MD
Course Director
Private Practice
Hematology/Oncology Cancer Program Director
Geisinger Lewistown Hospital

David F. Claxton, MD
Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Matthew S. Evans, MD
Assistant Professor of Medicine and Pathology
Penn State Health Hershey Medical Center
Penn State College of Medicine

Harold A. Harvey, MD
Course Director
Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Muhammad Hussain, MD
Resident Fellow
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Kim Leitzel, MSc
Senior Research Support Associate
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Kevin Rakszawski, MD
Resident Fellow
Penn State Health Milton S. Hershey Medical Center
Penn State Cancer Institute

Witold Rybka, MD
Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Cristina Truica, MD
Associate Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Kristine L. Widders, MD
Staff Physician
Penn State Health Milton S. Hershey Medical Center

Fee

Fee includes instruction, all listed meals and online handout materials.

$60 per person

$40 for Penn State Health Milton S. Hershey Employees

Registrations received after March 8, 2018 will incur a $25 late fee.

Cancellation

Cancellations received after March 1, 2018, will incur a $25 processing fee.

No refunds will be available after March 5, 2018. 

Please notify the Continuing Education Office if you need to cancel so that others may register. The University reserves the right to cancel or postpone any course or activity because of insufficient enrollment or other unforeseen circumstances.

If a program is canceled or postponed, the University will refund registration fees but cannot be held responsible for any related costs, charges, or expenses, including cancellation/change charges assessed by airlines or travel agencies. Preregistered participants will be notified if a program is filled or canceled.

Sponsor

A continuing education service of Penn State College of Medicine

Access (ADA)

Penn State encourages persons with disabilities to participate in its programs and activities. If you anticipate needing any type of special accommodation or have questions about the physical access provided, please contact Continuing Education at least one week in advance of your participation or visit.

Changes

Content and speakers for all programs are subject to change. Registrants will be notified of any significant updates.

Disclosure and Conflict of Interest (COI and educational balance)

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Complete faculty disclosure will be provided to program participants at the beginning of the activity.

University Nondiscrimination Policy

This publication is available in alternative media on request. The Pennsylvania State University is committed to the policy that all persons shall have equal access to programs, facilities, admission, and employment without regard to personal characteristics not related to ability, performance, or qualifications as determined by University policy or by state or federal authorities. It is the policy of the University to maintain an academic and work environment free of discrimination, including harassment. The Pennsylvania State University prohibits discrimination and harassment against any person because of age, ancestry, color, disability or handicap, genetic information, national origin, race, religious creed, sex, sexual orientation, gender identity, or veteran status and retaliation due to the reporting of discrimination or harassment. Discrimination, harassment, or retaliation against faculty, staff, or students will not be tolerated at The Pennsylvania State University. Direct all inquiries regarding the Nondiscrimination Policy to the Affirmative Action Director, The Pennsylvania State University, 328 Boucke Building, University Park, PA 16802-5901; tel 814-863-0471/TTY. US M.Ed. J6217

Jump to ...